Key terms

About JSPR

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest JSPR news

Apr 03 6:49am ET Jasper Therapeutics initiated with an Outperform at Evercore ISI by TipRanks Apr 03 6:40am ET Jasper Therapeutics initiated with an Outperform at Evercore ISI by TipRanks Mar 27 4:25pm ET Jasper Therapeutics initiated with an Outperform at RBC Capital by TipRanks Mar 21 10:46am ET Cantor Fitzgerald biotech analysts to hold analyst/industry conference call by TipRanks Mar 20 9:05am ET Buy Rating Affirmed for Jasper Therapeutics as Briquilimab Shows Market Potential in Chronic Urticaria Treatment by TipRanks Mar 20 9:00am ET Analysts’ Top Healthcare Picks: Jasper Therapeutics (JSPR), Alphatec Holdings (ATEC) by TipRanks Mar 19 8:03am ET Jasper announces first patient dosed in Phase 1b/2a SPOTLIGHT study by TipRanks Mar 18 5:45am ET Buy Rating for Jasper Therapeutics: Promising Prospects for Briquilimab in Treating Chronic Urticaria by TipRanks Mar 18 5:42am ET Jasper Therapeutics initiated with an Outperform at TD Cowen by TipRanks Mar 15 8:19am ET Jasper Therapeutics presents Phase 1b/2a data on briquilimab by TipRanks Mar 07 7:41am ET Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biomea Fusion (BMEA) and Jasper Therapeutics (JSPR) by TipRanks Mar 07 1:02am ET Bad News for Jasper Therapeutics, Inc. Stock: This New Risk Has Been Added by TipRanks Mar 04 1:15pm ET Buy Rating Affirmed: Jasper Therapeutics’ Progress and Potential in Addressing Unmet Needs in Chronic Urticaria Treatment by TipRanks Mar 04 7:31am ET Jasper Therapeutics reports Q4 EPS ($1.50), consensus ($1.61) by TipRanks Feb 27 7:48am ET Oppenheimer Reaffirms Their Buy Rating on Jasper Therapeutics (JSPR) by TipRanks Feb 26 2:25pm ET Buy Rating on Jasper Therapeutics Highlighting Briquilimab’s Potential in Chronic Urticaria Treatment by TipRanks Feb 23 8:02am ET Jasper Therapeutics presents data from preclinical briquilimab studies by TipRanks Feb 21 9:45am ET Buy Rating for Jasper Therapeutics: Promising Developments in CSU Treatment Pipeline and Anticipated Clinical Milestones by TipRanks Feb 12 3:53pm ET Fly Insider: Jasper, AMD among week’s notable insider trades by TipRanks Feb 07 4:23am ET Jasper Therapeutics Announces Offering Pricing Details by TipRanks Feb 07 4:23am ET Jasper Therapeutics Launches $50M Share Offering by TipRanks Feb 06 9:02am ET Jasper prices 3.9M shares at $12.95 per share in underwritten offering by TipRanks Feb 06 7:16am ET Oppenheimer Says There’s Room for up to 518% Gains in These 3 Under-the-Radar Stocks by TipRanks Feb 02 8:02am ET Jasper Therapeutics reports inducement grants under Nasdaq listing rule by TipRanks Jan 17 10:18am ET Jasper Therapeutics trading resumes by TipRanks Jan 17 10:13am ET Jasper Therapeutics trading halted, volatility trading pause by TipRanks Jan 05 8:36am ET Jasper Therapeutics announces key upcoming milestones by TipRanks

No recent press releases are available for JSPR

JSPR Financials

1-year income & revenue

Key terms

JSPR Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

JSPR Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming
Tim Wren, chief commercial officer for BSI Group, right, presents Kristalina Georgieva, chief executive officer of the World Bank Group, second right, with ISO 20121 certification for sustainable event management at an event during the spring meetings of the International Monetary Fund (IMF) and World Bank in Washington, DC, US, on Monday, April 15, 2024. The IMF and World Bank spring meetings in Washington are expected to draw thousands of delegates, observers and journalists from the fund's 190 member countries. Photographer: Samuel Corum/Bloomberg via Getty Images
Samuel Corum/Bloomberg/Getty Images
Geopolitical strife is roiling Wall Street. Here’s what investors are watching